AIM ImmunoTech (AIM) Stock Rockets On Coronavirus Treatment News

AIM ImmunoTech AIM Stock News

AIM ImmunoTech Inc (NYSEAMERICAN: AIM) has had an incredibly strong run in the market as of late, and those gains are continuing today. Today’s gains follow an announcement that the company’s flagship candidate, Ampligen, will be tested in Japan as a treatment for COVID-19. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AIM Stock Flies On COVID-19 Treatment Testing

In the press release, AIM ImmunoTech said that Ampligen is headed into testing as a potential treatment for the Wuhan coronavirus. However, it’s not just the testing that has investors excited, it’s who’s doing it.

According to the press release, the testing will take place at the National Institute of Infectious Diseases, also known as NIID, in Japan. The drug will be assessed in a collaboration between NIID and the University of Tokyo.

The company said that testing and research will be conducted by the Director of NIID’s Influenza Virus Research Center and Director of the World Health Organization Collaborating Center for Reference and Research on Influenza, Hideki Hasegawa, MD, PhD. Testing will also be conducted by Takeshi Ichinohe, PhD from the Department of Pathology at NIID and the Department of Biological Science and Technology at the Tokyo University of Technology.

In a statement, Thomas K. Equels, CEO at AIM, had the following to offer:

As we have been saying all along, this emerging pandemic is caused by a virus that has nearly identical regulatory RNA sequences to the original SARS coronavirus, known as SARS-CoV-1, in respect to pathogenesis. This means that the prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus. The WHO has recently renamed this emerging, highly pathogenic virus as SARS-CoV-2.

Ampligen had excellent antiviral activity against the earlier SARS coronavirus in U.S. National Institutes of Health-contracted animal experiments. In those studies of SARS-infected mice, Ampligen stands out as the only drug tested that conferred a significant survival effect: 100% of the Ampligen-treated mice survived, while none of the untreated mice survived. Because SARS-CoV-2 shares many critical similarities with SARS-CoV-1, Ampligen may have an important role to play in developing a protective early-onset therapy for this new highly pathogenic coronavirus in humans, where currently there is no known effective therapy. We are proud to work with Japan’s universally esteemed NIID in the battle to curb this emerging potential pandemic.

Why The News Is Sending The Stock Through The Roof

There are a few factors at play here. First and foremost, I don’t need to explain how serious of an issue the Wuhan coronavirus is. The world has been watching as the virus has infected more than 100,000 and killed nearly 4,000 in just a few months. Being on the leading edge of the fight against this pandemic is a great thing for AIM. However, the excitement goes far further.

If you’ve been following coronavirus-related stocks, you know that there are tons of companies working on developing a vaccine. In fact, there are a few vaccines that have already made it or are planned to make it to human and animal testing very soon.

However, there are few companies that have announced that they are actually working on a treatment. Perhaps even more importantly, to my knowledge, until today, none of these companies announced that treatments are headed into testing. AIM ImmunoTech is the first to push their potential treatment option to this stage.

Of course, this gives AIM a huge competitive advantage. After all, those who are the first to develop vaccines and treatments will likely see tremendous revenue opportunities ahead. With the company taking the lead on the treatment side of the coin, it only makes sense that investors are excited, pushing the stock for dramatic gains.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.